Platform randomised trial of treatments for COVID-19 in general practice - NL79504.068.21

Maastricht University0 个研究点目标入组 682 人开始时间: 2022年12月5日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Participant is willing and able to give informed consent for participation in the study., Participant is willing and able to comply with all trial procedures., Participant has an e-mail address, mobile phone and a laptop/computer/tablet that allows video calling., A positive test for COVID-19 (can be either RT-PCR, LAMP, antigen or self-test), which was taken fewer than 8 days ago (7 days or less)., The participant experiences symptoms of COVID-19. These symptoms may include, but are not limited to, shortness of breath, general feeling of being unwell, muscle pain, sore throat, diarrhoea, vomiting, fever, running nose, sneezing and coughing, and they must have had them for 7 days or less., Patients aged =18-60 years who are eligible for the annual influenza vaccine., Patients aged =60 years

•Currently admitted to hospital, Almost recovered (generally much improved and symptoms now mild or almost absent), Intervention specific (Montelukast): Known hypersensitivity to montelukast, Intervention specific (Montelukast): Concomitant use of montelukast, Intervention specific (Montelukast): Using Fenytoine, Fenobarbital, Rifampicine, Carbamazepine or St John’s wort

发起方